Longeveron INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

17 Mar 2026

LGVN

10-K: Longeveron Faces Liquidity Challenges Amid R&D Expansion

Longeveron Inc. reported a widened net loss for fiscal year 2025 and substantial doubt about its ability to continue as a going concern, despite advancing its lead product candidate, laromestrocel, in multiple clinical programs.

NASDAQ

28 Feb 2025

LGVN

Longeveron INC

10-K: Longeveron's 10-K Filing: Focus on HLHS and Alzheimer's Drives Strategic Shift

Longeveron's 10-K filing reveals a strategic focus on Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer's disease (AD) programs, alongside financial updates and risk assessments.

NASDAQ

11 Mar 2024

LGVN

Longeveron INC

10-K/A: Longeveron Files Amended 10-K to Correct Intellectual Property Disclosures, Clinical Programs Progressing

Longeveron Inc. has filed an amendment to its annual report to correct errors in the description of its intellectual property, while also providing updates on its clinical development programs.

NASDAQ

27 Feb 2024

LGVN

Longeveron INC

10-K: Longeveron Inc. Files 10-K, Highlights Progress in Clinical Trials and Manufacturing

Longeveron Inc.'s annual 10-K filing details the company's clinical development pipeline, manufacturing capabilities, and financial position for the year ended December 31, 2023.